Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1839MR)

This product GTTS-WQ1839MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1839MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4226MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ14732MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ5446MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ12797MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ9057MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ10810MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ14627MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14621MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW